Abstract: SA-PO0399
Association of Finerenone Use with Real-World Clinical Outcomes in Patients with CKD and Type 2 Diabetes (T2D)
Session Information
- CKM: Clinical - Epidemiology and Outcomes
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Cardiovascular-Kidney-Metabolic Health
- 602 Cardiovascular-Kidney-Metabolic Health: Clinical
Authors
- Pecoits-Filho, Roberto, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
- Estrella, Michelle M., University of California, San Francisco, San Francisco, California, United States
- Katta, Arvind, Bayer Corporation, Whippany, New Jersey, United States
- Zheng, Zihe, Bayer Corporation, Whippany, New Jersey, United States
- Beller Ferri, Mauricio, Bayer Corporation, Whippany, New Jersey, United States
- Betts, Keith A., Analysis Group Inc, Los Angeles, California, United States
- Earl, Jacob, Bayer Corporation, Whippany, New Jersey, United States
- Wu, Aozhou, Analysis Group Inc, Los Angeles, California, United States
- Sundar, Manasvi, Analysis Group Inc, Los Angeles, California, United States
- Aldworth, Carolina A R, Bayer Corporation, Whippany, New Jersey, United States
- Wang, Yunxun, Bayer Corporation, Whippany, New Jersey, United States
- Mares, Jon, Bayer Corporation, Whippany, New Jersey, United States
- Liu, Yue, Analysis Group Inc, Los Angeles, California, United States
- Zhu, Anyu, Analysis Group Inc, Los Angeles, California, United States
- Rui, Shumin, Analysis Group Inc, Los Angeles, California, United States
- Shlipak, Michael G., University of California, San Francisco, San Francisco, California, United States
Background
Evidence remains limited regarding the real-world effectiveness of finerenone in patients with CKD and T2D. This study compared cardiovascular (CV) outcomes between patients with and without finerenone use.
Methods
US adults with CKD and T2D initiating finerenone from July 2021 to June 2025 were identified in the Komodo Health claims database. Non-initiators, defined as patients without finerenone use, were propensity matched to users on demographic, clinical, and treatment characteristics. The index date was the finerenone initiation date for users and the date of a randomly selected eligible outpatient visit with a CKD diagnosis for non-initiators. The primary outcome was time to composite CV events (myocardial infarction, stroke, and hospitalization for heart failure [HHF]). Cumulative incidence functions and cause-specific Cox proportional hazards models were used to estimate event rates and hazard ratios (HRs), treating death as a competing risk.
Results
We identified 15,036 finerenone users and 2,864,308 non-initiators. After matching, 15,011 patients with well-balanced covariates were included in each cohort (mean age 68 years). Most patients had stage 3 (64%) or stage 4 CKD (21%) based on diagnosis codes. Over a mean follow-up of 15 months, 1,446 (10%) of finerenone users and 1,771 (12%) of non-initiators had composite CV events. Finerenone use was associated with a lower risk of CV events (HR 0.80; 95% CI, 0.75–0.86), driven by HHF with 945 (6%) and 1,147 (8%) events in finerenone users and non-initiators, respectively (HR 0.82; 95% CI, 0.75–0.89).
Conclusion
In this large US real-world study of patients with CKD and T2D, those treated with finerenone experienced a lower risk of CV events compared to matched patients without finerenone use, particularly in hospitalization for heart failure.
Funding
- Commercial Support – Bayer Corporation